Amyloid beta aggregation inhibitor

An object of the present invention is to provide a drug that suppresses aggregation of amyloid beta caused by a GNE gene mutation. The therapeutic pharmaceutical agent according to the present invention comprises a compound having an effect of increasing the amount of N-acetylneuraminic acid in cells. N-acetylneuraminic acid, an intermediate product produced downstream from N-acetylmannosamine in the N-acetylneuraminic acid biosynthetic pathway, N-acetylneuraminic acid derivatives as compounds contained in the therapeutic pharmaceutical agent N-acetyl mannosamine derivative, N-acetyl neuraminic acid-containing compound, N-acetyl neuraminic acid derivative-containing compound, N-acetyl mannosamine-containing compound, N-acetyl mannosamine derivative-containing compound, N-acetyl Examples include neuraminic acid degrading enzyme inhibitors, N-acetyl mannosamine degrading enzyme inhibitors, and intermediate product degrading enzyme inhibitors. [Selection] Figure 1